Katy de Valle

Katy de Valle

Auto-generated profile, based on publicly available information

Katy de Valle

Murdoch Children’s Research Institute, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
EYEppie M Yiu
Eppie M Yiu
CBCain R. Brockley
Cain R. Brockley
KLKatherine J. Lee
Katherine J. Lee
KCKate Carroll
Kate Carroll
KVKaty de Valle
Katy de Valle
MRMonique M. Ryan
Monique M. Ryan
Objective: To investigate differences in nerve cross-sectional area (CSA) as measured by peripheral nerve ultrasound in children with Charcot-Marie-Tooth disease type 1A (CMT1A) compared to healthy controls. Methods: This was a cross-sectional, matched, case-control study. CSA of the median, ulnar, tibial, and sural nerves was measured by peripheral nerve ultrasound. The mean difference in CSA between children with CMT1A and controls at each nerve site was determined. The relationship between nerve CSA and age/body metrics, and between nerve CSA and neurologic disability in CMT1A, was also evaluated. Results: Twenty-nine children with CMT1A and 29 age- and sex-matched controls were enrolled. Nerve CSA was significantly increased in children with CMT1A compared to controls (1.9- to 3.5-fold increase, p < 0.001). The increase in nerve CSA with age was disproportionately greater in those with CMT1A. Nerve CSA showed a strong positive linear correlation with age, height, and weight in both the CMT1A and control groups. Disease severity correlated with both nerve CSA and age. Conclusions: Children with CMT1A have significantly increased nerve CSA compared to controls, and the increase in nerve CSA with age is disproportionately greater in CMT1A, suggesting ongoing nerve hypertrophy throughout childhood. Nerve CSA correlates with neurologic disability. These findings demonstrate the utility of peripheral nerve ultrasound as a diagnostic tool in pediatric neuropathies, and as an outcome measure in natural history studies and clinical trials in CMT1A. Classification of evidence: This study provides Class IV evidence that measurement of nerve CSA by peripheral nerve ultrasound accurately identifies patients with CMT1A.

1 January 2010 in Pediatric Physical Therapy
Verified
Journal Article
Closed access
TPTamis W. Pin
Tamis W. Pin
KVKaty de Valle
Katy de Valle
BEBev Eldridge
Bev Eldridge
MGMary Galea
Mary Galea
The Alberta Infant Motor Scale (AIMS) is a standardized motor assessment for young infants. This study aimed to examine the reliability of the AIMS in a group of infants born at or before 29 weeks of gestation. Fifty-nine infants born preterm were recruited. Two experienced pediatric physical therapists participated in this reliability study. Infants were assessed at 4, 8, 12, and 18 months corrected age (CA). Intrarater reliability was high (intraclass correlation coefficient [ICC] > or =0.99). The ICC for interrater reliability varied from 0.85 to 0.97. The ICC was low at 4 and 18 months CA. The AIMS is reliable in evaluating motor development in infants born preterm. Clinicians should be cautious about using the AIMS in infants at very young ages and those approaching independent ambulation. Accurate placement of the window on a movement repertoire is crucial. Attention is required when using the AIMS in infants developing atypically.

10 April 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
JMJean Mah
Jean Mah
JFJia Feng
Jia Feng
MJMarni B. Jacobs
Marni B. Jacobs
TDTina Duong
Tina Duong
KCKate Carroll
Kate Carroll
DVDaniella Villano
Daniella Villano
Objectives To investigate motor function associations with age, sex, and D4Z4 repeats among participants with early-onset facioscapulohumeral muscular dystrophy (FSHD) type 1 as defined by weakness onset before 10 years of age. Methods We collected standardized motor assessments, including manual muscle testing (MMT), quantitative muscle testing, functional motor evaluations, and clinical severity scores (CSSs), at 12 Cooperative International Neuromuscular Research Group centers. To measure associations, we used linear regression models adjusted for sex, evaluation age, age at onset of weakness, and D4Z4 repeats. Results Among 52 participants (60% female, mean age 22.9 ± 14.7 years), weakness was most pronounced in the shoulder and abdominal musculature. Older enrollment age was associated with greater CSSs (p = 0.003). When adjusted for enrollment age, sex, and D4Z4 repeats, younger age at onset of facial weakness was associated with greater CSSs, slower velocities in timed function tests, and lower MMT scores (p < 0.05). Conclusion Significant clinical variability was observed in early-onset FSHD. Earlier age at onset of facial weakness was associated with greater disease severity. Longitudinal assessments are needed to determine the rate of disease progression in this population.

21 February 2018 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
SHSanne M. R. Hobbelink
Sanne M. R. Hobbelink
CBCain R. Brockley
Cain R. Brockley
RKRachel A. Kennedy
Rachel A. Kennedy
KCKate Carroll
Kate Carroll
KVKaty de Valle
Katy de Valle
EYEppie M Yiu
Eppie M Yiu
Introduction: The nerve sonographic features of Dejerine‐Sottas disease (DSD) have not previously been described.Methods: This exploratory cross‐sectional, matched, case–control study investigated differences in nerve cross‐sectional area (CSA) in children with DSD compared to healthy controls and children with Charcot–Marie–Tooth disease type 1A (CMT1A). CSA of the median, ulnar, tibial, and sural nerves was measured by peripheral nerve ultrasound. The mean difference in CSA between children with DSD, controls, and CMT1A was determined individually and within each group.Results: Five children with DSD and five age‐ and sex‐matched controls were enrolled. Data from five age‐matched children with CMT1A was also included. Group comparison showed no mean difference in nerve CSA between children with DSD and controls. Individual analysis of each DSD patient with their matched control indicated an increase in nerve CSA in three of the five children. The largest increase was observed in a child with a heterozygous PMP22 point mutation (nerve CSA fivefold larger than a control and twofold larger than a child with CMT1A). Nerve CSA was moderately increased in two children—one with a heterozygous mutation in MPZ and the other of unknown genetic etiology.Conclusions: Changes in nerve CSA on ultrasonography in children with DSD differ according to the underlying genetic etiology, confirming the variation in underlying pathobiologic processes and downstream morphological abnormalities of DSD subtypes. Nerve ultrasound may assist in the clinical phenotyping of DSD and act as an adjunct to known distinctive clinical and neurophysiologic findings of DSD subtypes. Larger studies in DSD cohorts are required to confirm these findings.

27 February 2016 in Journal of Pediatric Rehabilitation Medicine
Verified
Journal Article
Closed access
PDF file
KVKaty L. de Valle
Katy L. de Valle
ZDZoe E. Davidson
Zoe E. Davidson
RKRachel A. Kennedy
Rachel A. Kennedy
MRMonique M. Ryan
Monique M. Ryan
KCKate M. Carroll
Kate M. Carroll
PURPOSE: To record the use and perceived benefits of mainstream allied health services, complementary therapies, nutritional supplements and structured physical activity in a paediatric population of males with Duchenne or Becker muscular dystrophy.

1 August 2021 in Neuromuscular Disorders
Verified
Journal Article
Closed access
KVK. de Valle
K. de Valle
FDF. Dobson
F. Dobson
IWI. Woodcock
I. Woodcock
KCK. Carroll
K. Carroll
MRM.M. Ryan
M.M. Ryan
JMJ.L. McGinley
J.L. McGinley